-+ 0.00%
-+ 0.00%
-+ 0.00%

SeaStar Medical Q3 2026 net loss widens 30% to $4.53 million; Q3 2026 net revenue more than triples to $635,000

PUBT·11/11/2026 21:08:16
Listen to the news
SeaStar Medical Q3 2026 net loss widens 30% to $4.53 million; Q3 2026 net revenue more than triples to $635,000
  • SeaStar Medical’s third-quarter 2026 net loss widened 30% year over year to $4.53 million.
  • Net revenue more than tripled to $635,000, reflecting increased QUELIMMUNE sales.
  • Research and development expenses rose 93% to $3.57 million, driven primarily by increased clinical research, development and personnel costs.
  • The NEUTRALIZE-AKI pivotal trial enrolled 251 of 339 patients, with enrollment expected to finish by mid-2027.
  • Fulfillment of FDA post-approval SAVE Registry requirements enables hospitals to use QUELIMMUNE without the registry’s research infrastructure.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seastar Medical Holding Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611111605PRIMZONEFULLFEED9875734) on November 11, 2026, and is solely responsible for the information contained therein.